BioGend Therapeutics announced yesterday (18th) that its cartilage regeneration product Revocart has successfully obtained a medical device license in Hong Kong. The company will now accelerate promotion and sales in Hong Kong, Macau, and China’s Greater Bay Area (GBA).

Revocart’s international expansion continues to gain momentum, with approvals already secured in several countries including Cambodia, Thailand, the Philippines, and Malaysia, where it has entered the market. To date, 74 hospitals have adopted the product, and the number of patients treated has grown rapidly in recent years. The therapy is also being developed for additional indications, such as the shoulder, elbow, hip, and ankle, with strong growth potential expected ahead.

BioGend further disclosed that it is in licensing discussions with a U.S. company, with potential results expected as early as the second half of this year.

Beyond expanding Revocart’s overseas presence, BioGend is also focusing in the second half of the year on its Osteoinductive Factor (OIF) program, targeting open tibial fractures and non-union fractures. Results from the Phase II clinical trial for open tibial fractures are expected between late August and early September. If outcomes are favorable, the company plans to apply for a Phase III trial with the regulatory authorities.

Resource: 博晟生醫愛膝康報捷 取得香港醫療器械許可證